The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Compounds · Other compounds

Compounds this community declines to help with, and why — does this still hold?

T
ThibodeauTL3Regular2 Jun 2026#1

Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked.

I have seen SCALE (N Engl J Med, 2015) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows.

My reading is that the trial is sound for its own question and is being stretched to answer a different one. I might be wrong about that, which is why this is a topic rather than a correction.

What I would like from this discussion: someone who disagrees with me to say why, with the section of the paper they are relying on.

26 likes 2mo
G
GEldridgeTL3Regular14 Jun 2026 · edited#2

Worth separating two things that the opening post runs together.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

28 likes 1mo
AV
a.vestergaardTL2 Moderator23 Jun 2026#3

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

0 likes 1mo
GD
glossary_deskTL3Regular1 Jul 2026#4

Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.

5 likes 27d
AT
a.teixeiraTL2 Moderator8 Jul 2026#5

post #4 answers the question as asked. The question underneath it is different.

Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.

20 likes 20d
KB
k.brandl_deTL3Translator · DE15 Jul 2026#6
Thibodeau, post #1: Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually… Go to post

Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.

0 likes in reply to #1 13d
EN
e.nilsenTL2 Moderator21 Jul 2026#7

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

2 likes 7d
AL
aliquot_lineTL3Regular28 Jul 2026#8

Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not arbitrary. They exist because of failure modes that have happened in real people, not because of prudishness.

8 likes 7h

Suggested topics

TopicParticipantsRepliesViewsActivity
Coming back to: When "no data" is the complete and final answer
When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
LVAVHAPNV+77 82 12k 11mo
Research-use-only status: what it means legally and practically — a second dataset
Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with SURPASS-2 (…
TWONMSRFF+109 125 2k 16mo
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile
Posting this under the heading it deserves: Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with…
NATKBANDB+119 141 22k 20mo
Research-use-only status: what it means legally and practically — does this still hold?
Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Session topic: SELECT ( N Engl J Med , 2023). Please read…
DBETRT 2 309 9mo
AOD-9604 and the fragment hypothesis, revisited
Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SUSTAIN 6 ( N Engl J Med…
ARCDJBMRBR+40 44 2.8k 6mo

Related topics — sharing the tags custom synthesis, research use only, mislabelling

TopicParticipantsRepliesViewsActivity
Reading a regulatory notice rather than an article about it — what changed since
Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…
NSJRIBTYCC+28 32 640 13mo
Naming conventions for research peptides and the confusion they cause
Posting this under the heading it deserves: Naming conventions for research peptides and the confusion they cause Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with STEP 1 ( N…
ATNFPNDA+21 25 4.9k 22d
Second pass at: What to keep a record of at the point of payment
Second pass at: What to keep a record of at the point of payment — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually better than…
RSCVDSIAOO+14 18 1.9k 4mo
What a regulator's shortage notice actually authorises — what changed since
The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. A logistics question, since the…
JMMBUCRVW+22 26 53k 7mo
Second pass at: How to research a compound with no human data without deceiving yourself
Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med ,…
SVKBISCGP+64 71 2.5k 13mo